Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranitidine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2010
Lead Product(s) : Ranitidine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranitidine
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable
Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2017
Lead Product(s) : Ranitidine
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable